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Background: Many subjects in community have non-type 1 Brugada pattern ECG with atypical symp-
toms, relevance of which is not clear. Provocative tests to unmask type 1 Brugada pattern in these pa-
tients would help in diagnosing Brugada Syndrome. However sensitivity and speciﬁcity of provocating
drugs are variable.
Methods: We studied 29 patients referred to our institute with clinical presentation suggestive but not
diagnostic of Brugada or with non-Type 1 Brugada pattern ECG. Flecainide Challenge Test (FCT) was done
in these patients (IV Flecainide test in 4 patients and Oral Flecainide in 25 patients). Resting 12-lead ECG
with standard precordial leads and ECG with precordial leads placed 1 Intercostal space above were
performed after ﬂecainide administration every 5 min for ﬁrst 30 min and every 30 min thereafter until
ECG became normal or upto 6 h. The positivity was deﬁned as inducible Type 1 Brugada pattern in atleast
2 right sided leads.
Result: Median age was 35(range ¼ 5e65) years. In 16 (55%) patients the Type 1 Brugada pattern was
unmasked. There were no episodes of major AV block, atrial or ventricular tachyarrhythmia. Three groups
were considered for analysis: Group 1(n ¼ 9) e FCT Positive among patients with non-type 1 Brugada
ECG pattern, Group 2(n ¼ 4) e FCT Negative among the patients with non-type 1 Brugada ECG pattern,
and Group 3(n ¼ 7) e FCT Positive among patients with no spontaneous Brugada ECG pattern. Binary
logistic regression analysis found that family h/o SCD was predictive of FCT positivity in Group 1 (Odd’s
ratio 21, 95% Conﬁdence interval 1.04 to 698.83, p ¼ 0.004).
Conclusion: Oral ﬂecainide is useful and safe for unmasking of Type I Brugada pattern. In our study,
among the many variables studied, family history of sudden cardiac death was the only predictor of
ﬂecainide test positivity among those with non-Type 1 Brugada pattern.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Brugada Syndrome(BrS) is known for its catastrophic course
with heightened risk of sudden death in seemingly healthy pa-
tients. Diagnosis of BrS in patients with suggestive history is
established either by spontaneously occurring Type 1 Brugada ECG
pattern or by inducible Type 1 Brugada ECG pattern [1]. Non-Type 1
Brugada ECG pattern (Type 2 and Type 3 Brugada ECG patterns),
though are suggestive, are not diagnostic.i).
Rhythm Society.
ociety. Production and hosting byDrug challenge with sodium channel blockers is commonly
employed to unmask Type 1 Brugada pattern among those
without Type 1 Brugada ECG pattern. Studies [2e7] support the
importance of this type of tests for the appropriate evaluation of
patients with suspicious BrS and syncope of unknown etiology.
However, their sensitivity and speciﬁcity are variable and is
better with ajmaline compared to other agents [3e7]. Usage of
these drugs, (either the drug or the form of drug; example e
intravenous form of ﬂecainide), are limited in many countries
given their nonavailability. Given its limited utility, ajmaline is
not easily available in all electrophysiology laboratories. And
non-availability of intravenous ﬂecainide and procainamide in
many countries has made many laboratories to employ, freely
available oral ﬂecainide, to unmask Type 1 Brugada pattern, andElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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analysis of such data is limited.
On the other hand, many patients in community have non-type
1 Brugada pattern ECG with atypical symptoms, relevance of which
is not clear. Unmasking of type 1 Brugada pattern in these patients
would help in diagnosing BrS which has signiﬁcant impact on
prognosis and treatment options.
Though some studies [10,11] suggest repeating the test to
improve sensitivity, given the prevalence of the condition, more so
in eastern part of world, it may not be prudent to repeat the test in
all patients with negative result. Determining the predictors of
positive challenge would improve our understanding and facilitate
appropriate usage of these challenge tests.
We hypothesized that certain clinical & electrophysiological
characteristics of patients like aborted sudden cardiac death (SCD),
spontaneously occurring ventricular arrhythmia, inducible ven-
tricular arrhythmia or family history of BrS could help predict
positive ﬂecainide challenge test (FCT) and thereby in identiﬁcation
of patients with Type 1 Brugada pattern ewhich would help us in
better risk stratiﬁcation of these non-type 1 Brugada pattern
patients.
1.1. Study aims and objectives
We aimed to study the clinical and electrophysiological proﬁle
of patients who underwent ﬂecainide challenge test with the
objective to study and compare the clinical, genetic and electro-
physiological proﬁle of patients with positive and negative FCT in
patients without Type 1 Brugada ECG pattern.
2. Materials and methods
This study is a part of prospective registry, involving all
consecutive patients who underwent FCT for suspected BrS or to
look for inducibility of ECG pattern in non-Type 1 Brugada pattern
at Sree chitra Institute of Medical Sciences and Technology, Tri-
vandrum, India between January 2008 to April 2015.
2.1. Inclusion criteria
 Patients suspected to have Brugada by
 ECG e Non Type 1 Brugada pattern (Type 2 or Type 3 Brugada
pattern).
 F/h/o Brugada Syndrome.
 Patients for whom FCT was contemplated as a part of workup to
rule out Brugada syndrome.
 H/o aborted SCD.
 Unexplained Syncope/Pre-syncope.
 Documented ventricular arrhythmia.2.2. Exclusion criteria
 Evidence of structural heart disease that explains their
symptoms.
 Spontaneous Type 1 Brugada Pattern.
 Contraindication to Flecainide.
 Patient who did not give their consent.2.3. Flecainide challenge test and ECG criteria
 Flecainide Dose [1,9].
IV: 2 mg/Kg for 10 min as infusion, max 150 mg.Oral: 400 mg stat.
 ECG monitoring: (apart from continuous bed side telemetry).
 Normally placed 12 lead ECG and one space above right sided
leads (V1, V2, V3R, V4 R).
 For IV protocol: ECGs every minute for 10 min & every 5 min
thereafter till 30 min or till ECG abnormalities revert.
 For Oral Protocol: ECGs every 5min for ﬁrst 30min, and then at
30 min interval till 6 h or till abnormalities revert.
 Positivity: Inducible Type 1 Brugada pattern in atleast 2 right
sided leads were considered as positive FCT.
 Type 1 Brugada pattern is characterized by
 a coved ST-segment elevation 2 mm (0.2 mV) followed by a
negative T wave.
 Type 2 ST-segment elevation has a
 saddleback appearance with a high takeoff ST-segment
elevation of 2 mm, a trough displaying <1 mm ST eleva-
tion, and then either a positive or biphasic T wave.
 Type 3 has either a saddleback or coved appearance with an
ST-segment elevation of <1 mm.
Medical records of all patients were reviewed to extract infor-
mation on clinical, laboratory, ECG characteristics, details of ﬂe-
cainide challenge test, electrophysiological ﬁndings and other
relevant data.
Of the study population, 3 groups were considered for further
analysis for predicting positive response of FCT: Group 1 e FCT
Positive among patients with non-type 1 Brugada ECG pattern,
Group 2 e FCT Negative among the patients with non-type 1 Bru-
gada ECG pattern, and Group 3 e FCT Positive among patients with
no spontaneous Brugada ECG pattern.
2.4. Statistical analysis
Statistical analysis was performed using SPSS 16.0 for Windows
(SPSS Inc., Chicago, Illinois). Data are expressed as mean or median
(range). A Fischer’s Exact test was performed to test for statistical
signiﬁcance between categorical data and percentage frequencies.
Binary logistic regression with a forward stepwise model was uti-
lized to ﬁnd the predictors of a positive response to the drug
challenge test. The Hosmer and Lemeshow test was used to check
for model ﬁtness. A p value < 0.05 was considered to be statistically
signiﬁcant.
3. Results
Thirty two patients were considered for FCT; M ¼ 27 (M:F: 84%:
16%). 1 patient developed Type 1 Brugada Pattern just prior to
starting ﬂecainide, considered as spontaneous Type 1 Brugada
pattern and was excluded from analysis. 2 patients did not undergo
tests (technical or patient did not consent). Hence 29 patients un-
derwent FCT.
Of 29 subjects, 24 (83%) weremale.13 (44.8%) had Type 2 or Type
3 Brugada pattern (non-Type 1 Brugada pattern). Other 16 did not
have any type of Brugada pattern at the time of drug challenge, but
were considered for the challenge in view of their strongly suspi-
cious clinical proﬁle like family h/o BrS, aborted SCD, documented
ventricular arrhythmia, unexplained syncope (Table 1). 4 patients
had IV ﬂecainide challenge test and 25 patients had oral FCT. Choice
of IV or oral ﬂecainide was based only on availability of the intra-
venous form at that point of time (Fig. 1).
Sixteen (55%) patients were found to be positive on FCT (Fig. 2).
Of which 8 (50%) patients had Type 2 brugada pattern, 1 (6%) pa-
tient had Type 3 Brugada pattern, and 7 (44%) patients had no
spontaneous Brugada pattern. Median time to positivity was
Table 1
Baseline clinical proﬁle.
Non type 1 Brugada pattern No spontaneous Brugada pattern
Number of patients 13 (44.8%) 16 (55.2%)
Mean age (years) 38 (15e65) 34.3 (5e58)
M:F 12:1 12:4
Structurally normal heart 13 15
Asymptomatic 2 (15%) 2 (12.5%)
Pre-syncope 3 (23%) 4 (25%)
Syncope 7 (53%) 9 (56.2%)
Palpitations 2 (15%) 2 (12.5%)
History of aborted SCD 1 (7.6%) 3 (18.7%)
Family history of SCD 7 (53%) 6 (37.5%)
Family history of Brugada 2 (15%) 1 (6.2%)
Documented ventricular arrhythmia 2 (15%) 2 (12.5%)
Sinus Node dysfunction 1 (7.6%) 2 (12.5%)
Prominent or wide S wave in Lead I 9 (69%) 3 (18.7%)
Fragmented QRS 3 (23%) 0
Early repolarisation in inferolateral leads 5 (33%) 2 (12.5%)
SCD: sudden cardiac death.
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leads one space above improved sensitivity of the test by detecting
the induced Brugada pattern in 6 patients (37%) in whom test
would have been considered negative otherwise. PR interval, QRS
duration and QTc median difference compared to baseline was
23 ms (range ¼ 4 to þ54), 23 ms (range ¼ 0 to þ59) and 36 ms
(range¼11 toþ77), respectively. Therewere no episodes of major
AV block, atrial or ventricular tachyarrhythmia.
FCT was positive in 55% (Fig. 2a), of which 50% had Type 2
Brugada pattern in resting ECG and 44% had no evidence of any
Brugada pattern in their resting ECG (Fig. 2b). 2 of 4 patients tested
with IV FCT was positive and 14 of 25 patients tested with oral FCT
was positive (Fig. 2c). Median time for positivity was 150 min on
Oral FCT (n ¼ 14) (Fig. 2d).
Of the study population, 3 groups were considered for further
analysis: Group 1 e FCT Positive among patients with non-type 1
Brugada ECG pattern, Group 2 e FCT Negative among the patients
with non-type 1 Brugada ECG pattern, and Group 3 e FCT Positive
among patients with no spontaneous Brugada ECG pattern.
Multiple clinical factors and electrophysiological characteristics
e syncope/presyncope, arrhythmic symptoms, family history ofFig. 1. StudSCD, history of aborted SCD, family h/o Brugada, documented
ventricular arrhythmia on ILR/Holter/ECG, presence of sinus node
dysfunction and ECG characteristics like S in lead I, fragmentation
of QRS & early repolarisation pattern in inferolateral leads-were
considered for analysis of predicting the FCT response. Genetic
analysis of SCN5A mutations was not considered since it was not
available for all patients. Univariate analysis and binary logistic
regression (Tables 2 and 3) found that family h/o SCD was inde-
pendently predictive of FCT positivity (Odd’s ratio 21, 95% Conﬁ-
dence interval 1.04 to 698.83, p ¼ 0.004) among those with Type 2
or Type 3 Brugada pattern.4. Discussion
This study is ﬁrst of its kind from India to the best of our
knowledge. In this article we describe series of consecutive patients
with suspected BrS, and non-Type 1 Brugada pattern in whom
ﬂecainide was used to unmask the disease. Major results of our
study were: 1) family history of SCD predicted positivity of ﬂecai-
nide challenge test among those with Type 2 or Type 3 Brugada
pattern. 2) Oral FCT is safer and 3) increased sensitivity of detectingy ﬂow.
Fig. 2. Flecainide challenge test e characteristics.
Table 2
Characteristics of patients with respect to response to FCT and baseline ECG pattern e univariate and multivariate analysis.
Gp I Gp II Gp III Gp I vs Gp II Gp I vs Gp III
Fischer’s exact Logistic regression Fischer’s
exact
Logistic regression
OR 95% CI p value OR 95% CI p value
Sample size 9/13 (69.2%) 4/13 (30.8%) 7/16 (43.7%)
Mean Age (years) 41 (15e65) 29.25
(17e38)
36.4 (5e58)
M:F 9:0 3:1 7:0 0.307 1.000
Structurally Normal Heart 9 4 7
Presyncope 1 (11.1%) 2 (50%) 1 (14.2%) 0.210 0.12 0.007e2.17 0.546 0.700 0.75 0.03e14.57 0.849
Syncope 5 (55.5%) 1 (25%) 2 (28.5%) 0.187 7.5 0.73e76.77 0.153 0.437 3.125, 0.38e25.56 0.288
Palpitations 1 (11.1%) 1 (25%) 0 0.530 0.37 0.01e8.1 0.531 0.562 2.64 0.09e75.29 0.568
H/O Aborted SCD 1 (11.1%) 0 2 (28.5%) 0.690 1.58 0.05e47.51 0.789 0.400 0.31 0.02e4.41 0.389
F/h/o SCD 7 (77.7%) 0 3 (42.8%) 0.021 21 1.04e698.8 0.004 0.302 4.66 0.53e40.8 0.164
F/h/o Brugada 1 (11.1%) 1 (25%) 0 0.530 0.37 0.01e8.1 0.531 0.562 2.64 0.09e75.29 0.568
Documented V arrhythmia 2 (22.2%) 0 2 (28.5%) 1.000 0.28 0.06e102.3 0.120 1.000 0.71 0.07e6.92 0.07
Sinus Node dysfunction 1 (11.1%) 0 1 (14.2%) 0.690 1.58 0.05e47.51 0.789 0.700 0.75 0.03e14.57 0.849
Prominent or wide S
wave in Lead I
8 (88.8%) 1 (25%) 3 (43%) 0.051 24 1.11e518.6 0.64 0.105 10.6 0.82e138.2 0.742
Fragmented QRS 3 (33.3%) 0 0 0.496 0.0 0.13e0.82 0.62 0.212 0.0 0.13e0.83 0.63
Early repolarisation in
inferolateral leads
4 (44.4%) 1 (25%) 2 (28.5%) 1.000 2.4 0.17e32.8 0.18 0.632 0.8 0.07e8.47 0.105
EPS done 4 2 6
Inducible VT on EPS 2 0 2 0.400 5.0 0.15e166.6 0.368 0.547 2.0 0.14e26.73 0.600
SCD: sudden cardiac death; F/h/o: family history of; H/O: history of; VA: Ventricular arrhythmias; ILR:Implantable loop recorder; EPS: Electrophysiological Study. Gp I: Type 2/
3 Brugada Pattern patients e Positive FCT; Gp II: Type 2/3 Brugada Pattern patients e Negative FCT; Gp III: No spontaneous Brugada pattern patients e Positive FCT.
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4.1. Clinical predictors of positive response to drug challenge test
a) Family history of SCD.
In the present study, 14 (48.2%) out 29 patients who underwent
FCT had positive family history of SCD. Of which 10 patients (7 with
Type 2 or Type 3 brugada pattern and 3 with normal ECG) were
tested negative. Remaining 4, who had negative FCT had normalresting ECG. Interestingly, all 7 who had family history of SCD with
baseline Type 2 or type 3 Brugada pattern were tested positive. In
univariate and binary logistic regression analysis, family history of
SCD was identiﬁed as independent predictor of positive FCT.
Many previous studies [12e15] have shown that family history
of SCD does not predict increased event rate or inducible ventric-
ular arrhythmia or positive drug challenge test among BrS (all types
included). However none of them have analyzed the data for dif-
ferential risk between Type 1 and non Type 1 Brugada pattern.
Our study, by its nature, addresses this major clinical issue of
Table 3
Predictor of positive ﬂecainide challenge test by multivariate analysis by binary
logistic regression with a forward stepwise model.
B Exp(B) 95.0% C.I.for
EXP(B)
p-value
Lower Upper
Family history of SCD 21.896 3.231 1.040 698.812 0.004
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inducible Type 1 Brugada pattern is known to be poor compared to
those with negative drug challenge test. Therefore sodium channel
blocker challenge test can be considered in all patients with family
history of SCD in patients with baseline ECG showing Type 2 or
Type 3 Brugada pattern.
b) H/o Syncope.
Seventeen (58.6%) of 29 patients had presyncope (n ¼ 7) or
Syncope (n¼ 10), of which 09were tested FCT positive (6 with Type
2 or Type 3 Brugada pattern and other 3 had normal baseline ECG).
History of Syncope predicted the FCT positivity with an Odd’s ratio
of 7.5 between group 1 and group 2, though statistically insigniﬁ-
cant. Unlike other arrhythmic risk predicting studies [2,3,12e15],
our study did not ﬁnd the history of syncope to be useful for pre-
dicting positive response of drug challenge test. This possibly could
be because of our inclusion criteria of including all unexplained
syncope and conscious exclusion of deﬁnitive cases of Type 1
Brugada pattern and any other structural heart disease. Also likely
that the etiology of syncope need not be arrhythmic in this unse-
lected group.
c) Family history of Brugada.
In this study, 3 (10.3%) of 29 patients had family history of BrS, of
which 2 had Type 2 or Type 3 Brugada pattern (1 was FCT positive)
and other had normal baseline ECG (FCT was negative). Neither
univariate nor binary logistic regression, found this to be predictor
of FCT positivity among non-Type 1 Brugada pattern. This ﬁnding
extends the general notion [16] of limited usefulness of family
history of Brugada syndrome in predicting further clinical events
among BrS patients (all put together) to subgroup of non-Type 1
brugada patients also.
In our study, family history of SCD has the strongest prediction
with odds ratio of 21 (p ¼ 0.04). The anticipated genetic association
was more than that noted with symptomatic status with syncope.
This could be due to various reasons. First, the disease prevalence in
the family may be more than anticipated and many may be
asymptomatic. Second, syncope need not be arrhythmic. Third,
various biophysical factors affecting ionic channels and other ge-
netic moderators might be playing their role in determining the
nature of symptoms. A study by priori et al. [13], had shown that
upto 90% of family members of affected pro-bands could be
asymptomatic, more than half of them had negative phenotype
(silent mutation carriers) or had diagnostic ECG only after pro-
vocative challenge test. These results suggest the need of aggressive
approach towards family members of victims of SCD, more so in
those who have Type 2 or Type 3 Brugada pattern in resting ECG.
Long-term follow-up of patients diagnosed with BrS from the
FINGER registry [17] have shown that event rates in asymptomatic
patients is low (0.5% per year) and bigger in patients with aborted
SCD (7.7% per year) or syncope (1.9% per year). Our study, which
included largely symptomatic patients, and hence at higher risk,
portrays e family h/o SCD, as a strong predictor of unmasking of
Type 1 Brugada pattern with ﬂecainide challenge test. None of theasymptomatic patients in our study had any clinical event on
followup.
4.2. ECG predictors of positive response to drug challenge test
a)Prominent or Wide S in lead I.
Prominent S wave was deﬁned as >1 mm in depth and wide S
wave was deﬁned as > 1 mm in width on a ECG recorded with
standard speed of 25mm per sec and 10mV/mmvoltage. Twelve of
29 patients had prominent or wide S wave in lead I, of which 9
patients had Type 2 or Type 3 Brugada pattern (8 had positive FCT)
and 3 had normal baseline ECG (all 3 were positive for FCT). On
univariate analysis, this parameter failed to achieve statistical sig-
niﬁcance (p ¼ 0.057), though there was a trend towards increased
incidence among FCT positive patients.
A recent article by Calo et al. [18], had shown that prominent or
wide S in lead I was useful predictor of sudden death among Bru-
gada patients. Our study, though showed the trend of increased
incidence of prominent S in lead I among Type 2 or Type 3 Brugada
pattern with FCT positivity with a high odd’s ratio of 24, it was not
statistically signiﬁcant on either univariate or binary logistic
regression. This could be because of the study design with a
conscious exclusion of all deﬁnitive BrS patients who would be at
higher risk of SCD and also can be affected by smaller sample size.
Other ECG parameters like fragmentation of QRS and early repo-
larisation pattern were not found to be signiﬁcant in our study,
unlike other studies which report variable degree of signiﬁcance.
4.3. Oral FCT
Oral FCT though considered as alternative to Ajmaline provo-
cation test, due to its nonavailability, the FCT protocol is not yet
standardised. Bioavailability of oral ﬂecainide in its standard dose
averages 70% (range 60e86%), and higher bioavailability is achieved
by higher doses. Thus, in consistent with other studies [7,11], we
used single dose of 400 mg Flecainide tablets as the challenge dose
for oral FCT.
In this study, we observe that maximum time to positivity was
3 h and maximum time to subsequent normalization was 6 h. We
suggest, that there is no need to observe beyond 6 h.
4.4. Safety of oral FCT
Shahrzad et al. [15] observed some clinical and electrocardio-
graphic predictors of positive response to the intravenous sodium
channel blockers in patients suspected of the BrS. During test, a
transient episode of a second-degree atrioventricular block and
isolated ventricular ectopics, a QRS prolongation 30%, baseline
QRS duration in V1 110 ms and a ST-segment elevation 0.17 mV
in V2 had a good sensitivity and speciﬁcity for a positive response.
However, our study showed only an insigniﬁcant prolongation of
the QTc, QRS and PR intervals after drug administration. There were
neither 2nd nor 3rd degree AV block in our patients. Thereby
providing evidences for safety of oral FCT, nevertheless, we suggest
monitoring for ECG changes, arrhythmias and hemodynamic pa-
rameters as with any other drug challenge test.
4.5. Electrophysiological Study (EPS) e role in risk stratiﬁcation
Risk stratiﬁcation aimed at the identiﬁcation of patients at risk
for sudden death is an important goal of research teamsworldwide.
The inducibility of Ventricular tachycardia (VT)/ﬁbrillation (VF)
during EPS may forecast risk, although some studies [12,14,19]
failed to ﬁnd an association between inducibility and recurrence
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BrS. The role of EPS is still a controversial topic in patients with BrS;
Priori et al.in their PRELUDE study (PRogrammed ELectrical stim-
Ulation preDictive valuE) [12] showed that EPS was unable to
identify high-risk patients. In this study high proportion of patients
underwent EP study compared to other studies, but like other
studies failed to ﬁnd an association with FCT.
However given the variable sensitivity of provocating drugs,
Type 1 pattern may not be unmasked on some of the occasions.
Studies [10,11] have shown that repeating the test improves
sensitivity albeit with a warning of increased incidence of drug
adverse events. With the conﬂicting evidence of utility of repeating
FCT to improve sensitivity, coupled with the potential danger of
inducing malignant arrhythmia and associated mortality, we sug-
gest that, decision of repeating the test should be based on highly
suspicious clinical proﬁle. And in this regard, among those with
non-Type 1 Brugada pattern, a family h/o SCD could serve as a
clinical indicator to repeat the test on a different day in case of
initial negativity.
4.6. Study limitations
Our study has few limitations. First, small sample size is our
study’s major limitation. Second, we did not use other sodium
channel blocking drugs for challenge for comparison. Also we did
not intend to prove efﬁcacy and safety comparison between
intravenous and oral FCT. Third, repetition of the FCT in negative
patients was not done. Given the variable sensitivity of provocating
drugs, Type 1 pattern may not be unmasked on some of the occa-
sions. Few studies [10,11] have shown increased sensitivity on
repeating the test, but with potential risk of serious drug adverse
events. These studies had often used intravenous form of sodium
channel blocking drugs. However in our study, we did not have any
serious drug adverse events. Finally, though we screened for so-
dium channel mutation in few of patients, non-sodium channel
mutations were never screened for.
5. Conclusion
We conclude that oral ﬂecainide is useful and safe for
unmasking of Type 1 Brugada pattern. In our study, Family history
of sudden cardiac death was a major predictor of ﬂecainide test
positivity among those with non-Type 1 Brugada pattern.
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